Doximity price target lowered to $50 from $80 at Goldman Sachs

Goldman Sachs analyst David Roman lowered the firm’s price target on Doximity (DOCS) to $50 from $80 and keeps a Neutral rating on the shares after its Q4 results and below-consensus guidance. The company’s top-line growth rate is settling into a narrower range of 10%-11% through FY29 vs. FY25, the analyst tells investors in a research note. Goldman adds that it is forecasting relatively flat adjusted EBITDA margins in FY26 on lower y/y gross margins and investments in R&D.